Cytomegalovirus-Specific Immunotherapy for Glioblastoma Treatments

Over the last two decades, numerous studies have investigated the presence of human cytomegalovirus (CMV) within glioblastoma or gliomas; however, the results are severely conflicting. While a few researchers have suggested the potential benefits of cytotoxic T lymphocyte or dendritic cell-based vac...

Full description

Saved in:
Bibliographic Details
Published in:Brain tumor research and treatment 2022-07, Vol.10 (3), p.135
Main Authors: Jaehyun Ahn, Christopher Shin, Yeo Song Kim, Jae-sung Park, Sin-soo Jeun, Stephen Ahn
Format: Article
Language:Korean
Subjects:
Adoptive cell transfer
Cancer vaccines
Cytomegalovirus
Glioblastoma
Immunotherapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Over the last two decades, numerous studies have investigated the presence of human cytomegalovirus (CMV) within glioblastoma or gliomas; however, the results are severely conflicting. While a few researchers have suggested the potential benefits of cytotoxic T lymphocyte or dendritic cell-based vaccines for recurrent or newly diagnosed glioblastoma patients, several studies did not at all agree with the existence of CMV in glioblastoma cells. In this review, we summarized the conflicting results and issues about the detection of CMV in glioblastoma or glioma patients. We also provided the clinical data of published and unpublished clinical trials using CMV-specific immunotherapy for glioblastomas.
ISSN:2288-2405